Receptos

July 17, 2015July 17, 2015

Celgene to Acquire Receptos, Advancing the Potential of Ozanimod for the Treatment of Ulcerative Colitis

News, Ulcerative colitis

This week Celgene Corporation, a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein ... Read more

April 22, 2015September 28, 2016

Receptos Announces Positive Results for Ulcerative Colitis Therapy in Maintenance Period of Phase 2 Trial

Ulcerative colitis

Receptos, Inc. a biopharmaceutical company that develops drug candidates for the treatment of immune and metabolic diseases, recently announced positive results for the maintenance period of TOUCHSTONE, a Phase 2 clinical ... Read more

October 28, 2014September 28, 2016

MS Drug Candidate May Also Treat Ulcerative Colitis

News, Ulcerative colitis

Receptos, Inc., a San Diego-based biotechnology company, announced promising new clinical data for its drug candidate RPC1063 for ulcerative colitis. The drug was first discovered and synthesized at The Scripps Research Institute (TSRI) by ... Read more